Combination therapy with talquetamab and teclistamab in patients with relapsed or refractory multiple myeloma with extramedullary disease (EMD) achieved an overall response rate (ORR) of approximately 79%, with more than half of patients (54.4%) achieving a complete response or better[1]. The RedirecTT-1 trial defined EMD strictly as the presence of soft tissue plasmacytomas outside the bone marrow of at least 2 cm in size, confirmed by PET CT[1]. With the RP2R dose, the ORR in patients with EMD was even 85.7%, with 28.6% complete responses and 42.9% very good partial response (VGPR)[2]. Median duration of response was 12.9 months and median progression-free survival (PFS) in patients with EMD was 6.1 months, while median PFS was not reached in the RP2R group[2]. The combination of these two bispecific antibodies, targeting different antigens on myeloma cells, shows better results than monotherapy, where EMD responses are usually around 43%[1]. Treatment was well tolerated with manageable toxicity[2]. These results are considered groundbreaking in the treatment of extramedullary myeloma, which usually has a poor prognosis[1][2].